论文部分内容阅读
目的观察术后放疗联合复方苦参注射液治疗乳腺癌的临床疗效及其对患者细胞免疫功能及生活质量的影响,为临床乳腺癌患者术后治疗提供有力依据。方法回顾性分析我院乳腺放疗科2013年1月至2014年12月收治的128例术后放疗乳腺癌患者的临床诊治资料,其中术后放疗者64例为对照组,术后放疗联合复方苦参注射液静脉滴注者64例为观察组,共治疗6个月。于治疗前及治疗6个月后第二天检测两组患者的细胞免疫功能,比较两组患者美容效果、生活质量和不良反应。结果治疗6个月后观察组患者的CD3+、CD4+、NK细胞及CD4+/CD8+值较治疗前明显提高[(65.7±6.9)vs(58.3±8.1)、(38.7±4.9±6.9)vs(24.5±3.0)、(65.6±8.3)%vs(39.6±5.3)%、(1.18±0.21)vs(0.59±0.14)],而CD8+值较治疗前明显下降[(31.0±2.9)vs(42.7±4.5)],差异均有统计学意义(P<0.05);对照组患者的CD8+及NK细胞数较治疗前稍增加[(43.3±4.4)vs(42.1±4.9)、[(41.3±5.8)%vs(40.1±5.1)%],其他指标较治疗前略下降,差异均无统计学意义(P>0.05);观察组患者的美容优良率为92.2%(59/64),略优于对照组89.1%(57/64),差异无统计学意义(P>0.05);观察组患者的生存质量改善者52例(81.3%),明显高于对照组30例(46.9%),差异有统计学意义(P<0.05);观察组患者的皮肤反应和骨髓抑制明显优于对照组,差异均有统计学意义(P<0.01)。结论术后应用复方苦参注射液联合放疗治疗乳腺癌,其可减少不良反应,增强患者细胞免疫功能,且术后不会对乳房美容效果产生较大影响,有利于改善患者生活质量。
Objective To observe the clinical efficacy of postoperative radiotherapy combined with Compound Kushen Injection in the treatment of breast cancer and its effects on the cellular immune function and quality of life in patients with breast cancer and provide a strong basis for postoperative treatment of patients with breast cancer. Methods A retrospective analysis of clinical data of 128 cases of postoperative radiotherapy and breast cancer admitted to our department from January 2013 to December 2014 was performed. Among them, 64 cases of postoperative radiotherapy were control group. Postoperative radiotherapy combined with compound Participation in intravenous infusion of 64 patients for the observation group, a total of 6 months. Before treatment and the next 6 days after treatment, the cellular immune function of the two groups was tested. The cosmetic effect, quality of life and adverse reactions were compared between the two groups. Results After 6 months of treatment, the levels of CD3 +, CD4 +, NK cells and CD4 + / CD8 + in the observation group were significantly higher than those before treatment [(65.7 ± 6.9) vs (58.3 ± 8.1), (38.7 ± 4.9 ± 6.9) vs (24.5 ± (31.0 ± 2.9) vs (42.7 ± 4.5), respectively (P <0.05). The CD8 + (43.3 ± 4.4) vs (42.1 ± 4.9), (41.3 ± 5.8)% vs (41.3 ± 5.8)% (P <0.05), and the differences between the two groups were statistically significant 40.1 ± 5.1%). The other indexes decreased slightly compared with those before treatment, with no significant difference (P> 0.05). The excellent and good rate of the patients in the observation group was 92.2% (59/64), slightly better than that of the control group (89.1% (P> 0.05). The improvement of quality of life in the observation group was 52 cases (81.3%), which was significantly higher than that in the control group (30 cases, 46.9%), the difference was statistically significant (P <0.05). The skin reaction and myelosuppression in the observation group were significantly better than those in the control group, with significant differences (P <0.01). Conclusion Compound Kushen injection combined with radiotherapy for breast cancer after operation can reduce adverse reactions and enhance cellular immune function, and will not have a greater impact on breast cosmetic effect after operation, which is beneficial to improve the quality of life of patients.